• Journal of Hospice and Palliative Care
• /
• 제19권4호
• /
• pp.303-309
• /
• 2016

목적: 말기 암환자에서 악성 복수는 흔하게 발생하며, 그 자체가 나쁜 예후를 시사한다. 악성 복수에 대한 효과적이고, 최소한의 침습적인 방법으로 복수배액관 삽입이 제안되었다. 본 연구는 복수배액관 삽입을 시행한 말기 암환자들을 대상으로 복수배액관 시술의 효과와 부작용에 대하여 분석하고 시술 후 예후에 영향을 미치는 요인을 알아보기 위하여 시행되었다. 방법: 서울 소재 일개 3차 의료기관 호스피스 병동에 2010년 1월 1일부터 2013년 12월 31일까지 입원한 말기 암환자 2,608명 중 복수배액관 삽입을 시행한 67명의 환자들의 의무기록을 조사하였다. 인구학적 정보, 완화의료 수행지수, 혈액검사, 복수 배액관 유지 기간, 시술 합병증의 종류와 빈도, 항생제 사용 여부와 기간, 시술 후 생존기간을 분석하였다. 복수 배액관 삽입 후 생존기간에 영향을 미치는 요인을 평가하기 위해 단변량 및 다변량 콕스 비례위험 회귀분석을 실시하였다. 결과: 총 67명의 연구대상자 중 원발암은 간암 및 담도암과 위암이 가장 흔하였다. 복수배액관 시술 후 복수관련 증상의 호전은 55명(82.1%)에서 있었다. 시술 후 합병증은 통증(19.4%), 누수(14.9%), 배액관 빠짐(7.5%), 배액관 막힘(6%), 발열(4.5%)이었다. 복수배액관 시술 후 생존기간에 영향을 주는 인자는 다변량 콕스 비례위험 회귀분석 결과 완화의료 수행지수(HR 0.73; P=0.045), 저나트륨혈증(HR 2.77; P=0.003)이었다. 결론: 복수를 동반한 말기 암환자에서 복수 배액관 시술 시, 완화의료 수행지수와 저나트륨혈증은 예후 인자로 사용될 수 있을 것이다. 추후 대규모의 전향적 연구가 요구된다.

• 대한약침학회지
• /
• 제12권3호
• /
• pp.5-24
• /
• 2009

Injinho-tang(IJ) has been used for the treatment of hepatobiliary diseases. This study was performed to observe the effect of IJ extract on the hepatocellular carcinogenesis and hepatic cirrhosis induced by Diethylnitrosamine(DENA) and $CCl_4$ in Rats. Experimental groups were divided into two ; 8th and 12th week group, and subdivided into four; normal group(Nor), hepatocellular cancer and hepatic cirrhosis inducing control group(Con), and IJ extract 260mg/kg/day(IJA) or 520mg/kg/day(IJB) administered groups to Con. The results obtained are as follows: The body weight was decreased in the Con, IJA and IJB compared with the Nor from the 2nd week to the 12th week. The weight of liver and the weight of liver/100g body weight were decreased significantly in Con, IJA and IJB compared with the Nor. The activities of aspartate aminotransferase(AST) and alanine aminotransferase(ALT) were significantly increased in the Con compared with Nor, but decreased in the IJA and IJB compared with Con from the 8th week group. The activities of alkaline phosphatase(ALP), lactacte dehydrogenase (LDH) and alpha fetoprotein(AFP) were increased significantly in the Con compared with Nor, but decreased in the IJA and IJB compared with Con. The activities of superoxide dismutase(SOD) were decreased in the IJA and IJB compared with Con, but the activities of catalase were increased in the IJA and IJB compared with Con. According to the light and electron microscopical observation, IJA and IJB improved the morphological and histopathological changes of the liver injured by DENA and $CCl_4$. The number of hepatic p53 positive cells was decreased in the IJA and IJB compared with Con. These results suggest that administration of IJ extract suppress or retard DENA and $CCl_4$-induced hepatocelluar carcinogenesis and hepatic cirrhosis in rats.

• Korean Journal of Radiology
• /
• 제23권12호
• /
• pp.1260-1268
• /
• 2022

Objective: To propose standardized MRI-proton density fat fraction (PDFF) cutoff values for diagnosing hepatic steatosis, evaluated using contemporary PDFF measuring methods in a large population of healthy adults, using histologic fat fraction (HFF) as the reference standard. Materials and Methods: A retrospective search of electronic medical records between 2015 and 2018 identified 1063 adult donor candidates for liver transplantation who had undergone liver MRI and liver biopsy within a 7-day interval. Patients with a history of liver disease or significant alcohol consumption were excluded. Chemical shift imaging-based MRI (CS-MRI) PDFF and high-speed T2-corrected multi-echo MR spectroscopy (HISTO-MRS) PDFF data were obtained. By temporal splitting, the total population was divided into development and validation sets. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic performance of the MRI-PDFF method. Two cutoff values with sensitivity > 90% and specificity > 90% were selected to rule-out and rule-in, respectively, hepatic steatosis with reference to HFF ≥ 5% in the development set. The diagnostic performance was assessed using the validation set. Results: Of 921 final participants (624 male; mean age ± standard deviation, 31.5 ± 9.0 years), the development and validation sets comprised 497 and 424 patients, respectively. In the development set, the areas under the ROC curve for diagnosing hepatic steatosis were 0.920 for CS-MRI-PDFF and 0.915 for HISTO-MRS-PDFF. For ruling-out hepatic steatosis, the CS-MRI-PDFF cutoff was 2.3% (sensitivity, 92.4%; specificity, 63.0%) and the HISTO-MRI-PDFF cutoff was 2.6% (sensitivity, 88.8%; specificity, 70.1%). For ruling-in hepatic steatosis, the CS-MRI-PDFF cutoff was 3.5% (sensitivity, 73.5%; specificity, 88.6%) and the HISTO-MRI-PDFF cutoff was 4.0% (sensitivity, 74.7%; specificity, 90.6%). Conclusion: In a large population of healthy adults, our study suggests diagnostic thresholds for ruling-out and ruling-in hepatic steatosis defined as HFF ≥ 5% by contemporary PDFF measurement methods.